Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
UCB, Inc. ( UCB Korea Co. Ltd. )
ClinicalTrials.gov Identifier:
NCT01523301
First received: January 27, 2012
Last updated: July 31, 2014
Last verified: July 2014

January 27, 2012
July 31, 2014
April 2012
October 2014   (final data collection date for primary outcome measure)
Change from the Baseline to the end of Maintenance Period in the score of the Hamilton Depression Scale (HAM-D) [ Time Frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01523301 on ClinicalTrials.gov Archive Site
  • Change from Baseline to the end of Maintenance Period in the score of Beck Depression Inventory (BDI-II) [ Time Frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15) ] [ Designated as safety issue: No ]
  • Change from Baseline to the end of Maintenance Period in the score of Unified Parkinson's Disease Rating Scale (UPDRS) part II (Activities of Daily Living-ADL subscale) [ Time Frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15) ] [ Designated as safety issue: No ]
  • Change from Baseline to the end of Maintenance Period in the score of Unified Parkinson's Disease Rating Scale (UPDRS) part III (motor subscale) [ Time Frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15) ] [ Designated as safety issue: No ]
  • Change from Baseline to the end of Maintenance Period in the combined score of Unified Parkinson's Disease Rating Scale (UPDRS) part II (ADL) plus part III (motor subscale) [ Time Frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15) ] [ Designated as safety issue: No ]
  • Change from Baseline to the end of Maintenance Period in the score of Apathy Scale (AS) [ Time Frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15) ] [ Designated as safety issue: No ]
  • Change from Baseline to the end of Maintenance Period in the score of Snaith-Hamilton Pleasure Scale (SHAPS) [ Time Frame: From Baseline (Week 0) to end of Maintenance Period (up to Week 15) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Rotigotine Versus Placebo to Evaluate the Efficacy on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine in Depressive Symptoms in Idiopathic Parkinson's Disease Patients

The purpose of this study is to show superiority of Rotigotine over placebo on improvement of depressive symptoms in subjects with idiopathic Parkinson's disease.

The study includes a maximum 2-week Screening Period, a maximum 4-week Titration Period for early-stage Parkinson's disease or maximum 7-week Titration Period for advanced-stage Parkinson's disease, 8-week Maintenance Period, a maximum 6-day De-escalation Period for early-stage Parkinson's disease or maximum 12-day De-escalation Period for advanced-stage Parkinson's disease and 30-day Safety Follow-Up Period.

The maximum study durations for an individual subject with early-stage Parkinson's disease and with advanced-stage Parkinson's disease will be 19 weeks and 23 weeks, respectively.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Idiopathic Parkinson's Disease
  • Drug: Rotigotine

    Transdermal Patch

    Content:

    2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)

    • For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period
    • For advanced-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period
  • Drug: Placebo Patch

    Transdermal Patch

    Size:

    10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2 Subjects randomized to placebo will receive matching placebo patches

  • Experimental: Rotigotine
    Rotigotine, daily doses, treatment group
    Intervention: Drug: Rotigotine
  • Placebo Comparator: Placebo
    Placebo, daily doses, placebo group
    Intervention: Drug: Placebo Patch
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
392
October 2014
October 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects ≥ 20 years old
  • Subjects diagnosed with idiopathic Parkinson's disease (according to the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria for Parkinson's disease) at modified Hoehn and Yahr Scale stages I-III; do not have motor fluctuations, dyskinesia, and have stable motor symptom at least 4 weeks prior to the Screening Visit as judged by the local investigator
  • Subject has a Hamilton Depression Scale (HAM- D) score ≥ 16 as evidenced by depression rating scale study in Parkinson's disease (Schrag A et al, 2007)
  • Subject has a Mini-Mental State Examination (MMSE) score ≥ 24
  • If subject is taking Levodopa (L-DOPA) and derivatives, Monoamine Oxidase (MAO) B-inhibitors, anticholinergics agents, Catechol-O-Methyl Transferase (COMT) inhibitor or N-Methyl-D-Aspartate (NMDA) antagonist, he/she must have been on stable dose for at least 28 days prior to the Screening Visit
  • If subject is taking an antidepressant drug such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), bupropion, tricyclic antidepressants (TCAs), he/she must have been on a stable dose for at least 28 days prior to the Screening Visit and be maintained on that dose for the duration of the trial

Exclusion Criteria:

  • Subject has any medical or psychiatric condition (ie, bipolar disorder, dementia, hallucinations or psychosis) that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study
  • Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('Yes') to either Question 4 or Question 5 of the C-SSRS at Screening (Visit 1)
  • Current psychotherapy or behavior therapy while participating in this study
  • Subject has received electroconvulsive therapy within 12 weeks of the Screening Visit
  • Subject who has received dopamine agonists within 28 days of the Screening Visit
  • Subject who has received neuroleptics, methylphenidate, reserpine, alpha-methyldopa, metoclopramide, levosulpiride or amphetamine derivatives within 28 days of the Screening Visit
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01523301
SP1041
No
UCB, Inc. ( UCB Korea Co. Ltd. )
UCB Korea Co. Ltd.
Not Provided
Study Director: UCB Clinical Trial Call Center +1 877 822 9493 (UCB)
UCB, Inc.
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP